Biocept announces participation in an investigator-initiated study to better understand the development and progression of metastatic breast cancer to the central nervous system

San diego--( business wire )--biocept, inc. (nasdaq: bioc), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investigator-initiated, non-therapeutic pilot study to evaluate the cerebrospinal fluid tumor and immune cell microenvironment in patients with metastatic breast cancer and brain metastases and/or leptomeningeal disease. the study is designed to identify biomarkers associated with central nervous system (cns) metastasis, enabling a better understanding of treatment response, prognosis, and treatment resistance that may improve the management of cns disease in patients with metastatic breast cancer.
BIOC Ratings Summary
BIOC Quant Ranking